Protection of study subjects
FDA issues a draft guidance specifying the responsibilities investigators have to protect the rights and safety of patients participating in clinical trials. FDA says the agency became increasingly aware that current guidance and regulation - codified primarily in the 1970s - did not adequately address the increasing complexity of the modern clinical enterprise, including outsourcing. Comments are due by July 9...
You may also be interested in...
Health technology assessment body NICE says that Revlimid fights cancer cells in a different way to current treatments which should help reduce resistance and improve disease outcomes.
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.